New-York-Presbyterian Brooklyn Methodist Hospital/Weill Cornell Medicine, Brooklyn, NY, USA.
New York University Long Island, Mineola, NY, USA.
Expert Rev Hematol. 2024 Oct;17(10):749-753. doi: 10.1080/17474086.2024.2389988. Epub 2024 Aug 8.
Multiple myeloma (MM) is a plasma cell neoplasm, which accounts for 1-2% of cancers and approximately 17% of hematological malignancies in the United States each year. Fifty percent of patients with symptomatic MM have three or more primary care visits before being referred to a specialist, which is greater than any other cancer. A delay in the diagnosis of multiple myeloma has been shown to negatively impact the clinical course of the disease; patients with longer diagnostic intervals have been shown to experience shorter disease-free survival and higher rates of treatment-related complications.
We performed a retrospective analysis of patients diagnosed with MM in our institution, to determine the time from the first detectable lab abnormality to the diagnosis of MM.
We included 92 patients in this study. Fifty-two percent of patients had isolated anemia at the time of diagnosis. Twenty-nine percent of patients had a delay in diagnosis of ≥1 year, while 18% had a delay of ≥3 years. Nine patients in our cohort had anemia and an elevated serum total protein (31%). This group had the longest time to diagnosis with a median of 38 months.
Our results did not show any difference in time to diagnosis by race, ethnicity, gender, or socioeconomic status.
多发性骨髓瘤（MM）是一种浆细胞瘤，每年占美国癌症的 1-2%，占血液系统恶性肿瘤的 17%左右。有症状的 MM 患者中有 50%在被转介给专家之前已经有三次或更多次的初级保健就诊，这比任何其他癌症都多。多发性骨髓瘤诊断的延迟已被证明对疾病的临床过程产生负面影响；诊断间隔时间较长的患者无病生存期较短，治疗相关并发症的发生率较高。
我们对我院诊断为 MM 的患者进行了回顾性分析，以确定从首次可检测到的实验室异常到 MM 诊断的时间。
本研究纳入 92 例患者。52%的患者在诊断时存在孤立性贫血。29%的患者诊断延迟≥1 年，18%的患者诊断延迟≥3 年。我们队列中的 9 例患者贫血和血清总蛋白升高（31%）。这一组的诊断中位时间最长，为 38 个月。
我们的结果显示，种族、民族、性别或社会经济地位与诊断时间无差异。
